Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients

Figure 1

Expression of Foxp3+ and TIGIT+Foxp3+ γδ T cells from AML patients and HIs. (a) The expression of Foxp3+ and TIGIT+Foxp3+ γδ T cells from a healthy individual (HI), a de novo AML patient, an AML patient in nonremission (AML-NR), and an AML patient in complete remission (AML-CR). (b) Comparison of the percentage of Foxp3+ and TIGIT+Foxp3+ γδ T cells from AML patients and HIs. (c) Heatmap representing the frequency of Foxp3+ and TIGIT+Foxp3+ γδ T cells in AML patients and HIs. a: Foxp3+ γδ T cells; b: TIGIT+Foxp3+ γδ T cells.

(a)

(b)

(c)